Stocktwits on MSN
MIRM stock clocks best day in 4.5 months on liver disease trial data: Retail eyes buyout at a premium
In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases. ・The ...
New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) ...
Global warming has accelerated since 2015, according to a new study by the Potsdam Institute for Climate Impact Research (PIK). After accounting for known natural influences on global temperature, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results